CD8+/FOXP3+-ratio in osteosarcoma microenvironment separates survivors from non-survivors: A multicenter validated retrospective study

OncoImmunology

Volumn 4, Issue 3, 2015, Pages 1-10

  Fritzsching, Benedikt ^a   Fellenberg, Joerg ^b   Moskovszky, Linda ^c   Sápi, Zoltan ^c   Krenacs, Tibor ^c   Machado, Isidro ^d   Poeschl, Johannes ^a   Lehner, Burkhard ^b   Szendrõi, Miklos ^c   Bosch, Antonio Llombart ^e   Bernd, Ludger ^f   Csóka, Monika ^g   Mechtersheimer, Gunhild ^b   Ewerbeck, Volker ^b   Kinscherf, Ralf ^h   Kunz, Pierre ^b  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c SEMMELWEIS UNIVERSITY   (Hungary)

^d INSTITUTO VALENCIANO DE ONCOLOGÍA   (Spain)

^e UNIVERSITY OF VALENCIA   (Spain)

^f Department of Head and Neck Surgery   (Germany)

^g SEMMELWEIS UNIVERSITY   (Hungary)

^h PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

CD8 FOXP3 ratio; CD8+ T cells; Immunoscore; Osteosarcoma; Regulatory T cells; Tumor microenvironment

Indexed keywords

CD8 ANTIGEN; METHOTREXATE; TRANSCRIPTION FACTOR FOXP3;

ADJUVANT CHEMOTHERAPY; ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVOR; CD8+ T LYMPHOCYTE; CELL DENSITY; CELL HETEROGENEITY; CHILD; COHORT ANALYSIS; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; OSTEOSARCOMA; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION;

EID: 84947267216     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/2162402X.2014.990800     Document Type: Article

References (57)

1. Khanna C, Fan TM, Gorlick R, Helman LJ, Kleinerman ES, Adamson PC, Houghton PJ, Tap WD, Welch DR, Steeg PS et al. Toward a drug development path that targets metastatic progression in osteosarcoma. Clin Cancer Res 2014; 20:4200-9; PMID:24803583; http://dx.doi.org/10.1158/1078-0432.CCR-13-2574
2. Iwata S, Ishii T, Kawai A, Hiruma T, Yonemoto T, Kamoda H, Asano N, Takeyama M. Prognostic factors in elderly osteosarcoma patients: a multi-institutional retrospective study of 86 cases. Ann Surg Oncol 2014; 21:263-8; PMID:23975321; http://dx.doi.org/10.1245/s10434-013-3210-4
3. Bakhshi S, Radhakrishnan V. Prognostic markers in osteosarcoma. Expert Rev Anticancer Ther 2010; 10:271-87; PMID:20132002; http://dx.doi.org/10.1586/era.09.186
4. Poos K, Smida J, Nathrath M, Maugg D, Baumhoer D, Neumann A, Korsching E. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database 2014; PMID:24865352; http://dx.doi.org/10.1093/database/bau042
5. Smida J, Baumhoer D, Rosemann M, Walch A, Bielack S, Poremba C, Remberger K, Korsching E, Scheurlen W, Dierkes C et al. Genomic alterations and allelic imbalances are strong prognostic predictors in osteosarcoma. Clin Cancer Res 2010; 16:4256-67; PMID:20610556; http://dx.doi.org/10.1158/1078-0432.CCR-10-0284
6. Galon J, Pages F, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G et al. Cancer classification using the Immunoscore: a worldwide task force. J Transl Med 2012; 10:205; PMID:23034130; http://dx.doi.org/10.1186/1479-5876-10-205
7. Mlecnik B, Tosolini M, Kirilovsky A, Berger A, Bindea G, Meatchi T, Bruneval P, Trajanoski Z, Fridman WH, Pages F et al. Histopathologic-based prognostic factors of colorectal cancers are associated with the state of the local immune reaction. J Clin Oncol 2011; 29:610-8; PMID:21245428; http://dx.doi.org/10.1200/JCO.2010.30.5425
8. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013; 14:1014-22; PMID:24048123; http://dx.doi.org/10.1038/ni.2703
9. Oleinika K, Nibbs RJ, Graham GJ, Fraser AR. Suppression, subversion and escape: the role of regulatory T cells in cancer progression. Clin Exp Immunol 2013; 171:36-45; PMID:23199321; http://dx.doi.org/10.1111/j.1365-2249.2012.04657.x
10. Wang HY, Wang RF. Regulatory T cells and cancer. Curr Opin Immunol 2007; 19:217-23; PMID:17306521; http://dx.doi.org/10.1016/j.coi.2007.02.004
11. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G. Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumours, with a characterization of the tumour phenotype. Cancer Immunol Immunother 1992; 34:241-51; PMID:1311218; http://dx.doi.org/10.1007/BF01741792
12. Trieb K, Lechleitner T, Lang S, Windhager R, Kotz R, Dirnhofer S. Evaluation of HLA-DR expression and Tlymphocyte infiltration in osteosarcoma. Pathol Res Pract 1998; 194:679-84; PMID:9820863; http://dx.doi.org/10.1016/S0344-0338(98)80126-X
13. Wang L, Zhang Q, Chen W, Shan B, Ding Y, Zhang G, Cao N, Liu L, Zhang Y. B7-H3 is overexpressed in patients suffering osteosarcoma and associated with tumor aggressiveness and metastasis. PloS One 2013; 8: e70689; PMID:23940627; http://dx.doi.org/10.1371/journal.pone.0070689
14. Kunz P, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Poeschl J, Lehner B, Szendroi M, Ewerbeck V, Kinscherf R et al. Osteosarcoma microenvironment: wholeslide imaging and optimized antigen detection overcome major limitations in immunohistochemical quantification. PloS One 2014; 9:e90727; PMID:24594971; http://dx.doi.org/10.1371/journal.pone.0090727
15. Bielack SS, Kempf-Bielack B, Delling G, Exner GU, Flege S, Helmke K, Kotz R, Salzer-Kuntschik M, Werner M, Winkelmann W et al. Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. J Clin Oncol 2002; 20:776-90; PMID:11821461; http://dx.doi.org/10.1200/JCO.20.3.776
16. Collins M, Wilhelm M, Conyers R, Herschtal A, Whelan J, Bielack S, Kager L, Kuhne T, Sydes M, Gelderblom H et al. Benefits and adverse events in younger versus older patients receiving neoadjuvant chemotherapy for osteosarcoma: findings from a meta-analysis. J Clin Oncol 2013; 31:2303-12; PMID:23669227; http://dx.doi.org/10.1200/JCO.2012.43.8598
17. Nathan SS, Healey JH. Demographic determinants of survival in osteosarcoma. Ann Acad Med Singapore 2012; 41:390-9; PMID:23052433
18. Bacci G, Longhi A, Versari M, Mercuri M, Briccoli A, Picci P. Prognostic factors for osteosarcoma of the extremity treated with neoadjuvant chemotherapy: 15-year experience in 789 patients treated at a single institution. Cancer 2006; 106:1154-61; PMID:16421923; http://dx.doi.org/10.1002/cncr.21724
19. Mankin HJ, Hornicek FJ, Rosenberg AE, Harmon DC, Gebhardt MC. Survival data for 648 patients with osteosarcoma treated at one institution. Clin Orthop Relat Res 2004:286-91; PMID:15577500; http://dx.doi.org/10.1097/01.blo.0000145991.65770.e6
20. Kunz P, Fellenberg J, Moskovszky L, Sapi Z, Krenacs T, Machado I, Poeschl J, Lehner B, Szendroi M, Ruef P et al. Improved survival in osteosarcoma patients with atypical low vascularization. Ann Surg Oncol 2014; 22(2):489-96; http://dx.doi.org/.1245/s10434-014-4001-2
21. Botter SM, Neri D, Fuchs B. Recent advances in osteosarcoma. Curr Opin Pharmacol 2014; 16:15-23; PMID:24632219; http://dx.doi.org/10.1016/j.coph.2014.02.002
22. Luetke A, Meyers PA, Lewis I, Juergens H. Osteosarcoma treatment – where do we stand? A state of the art review. Cancer Treat Rev 2014; 40:523-32; PMID:24345772; http://dx.doi.org/10.1016/j.ctrv.2013.11.006
23. Allison DC, Carney SC, Ahlmann ER, Hendifar A, Chawla S, Fedenko A, Angeles C, Menendez LR. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012; 2012:704-872; PMID:22550423; http://dx.doi.org/10.1155/2012/704872
24. Franz B, Fritzsching B, Riehl A, Oberle N, Klemke CD, Sykora J, Quick S, Stumpf C, Hartmann M, Enk A et al. Low number of regulatory T cells in skin lesions of patients with cutaneous lupus erythematosus. Arthritis Rheum 2007; 56:1910-20; PMID:17530636; http://dx.doi.org/10.1002/art.22699
25. Fritzsching B, Haas J, Konig F, Kunz P, Fritzsching E, Poschl J, Krammer PH, Bruck W, Suri-Payer E, Wildemann B. Intracerebral human regulatory T cells: analysis of CD4C CD25C FOXP3C T cells in brain lesions and cerebrospinal fluid of multiple sclerosis patients. PloS One 2011; 6:e17988; PMID:21437244
26. Fritzsching B, Oberle N, Pauly E, Geffers R, Buer J, Poschl J, Krammer P, Linderkamp O, Suri-Payer E. Naive regulatory T cells: a novel subpopulation defined by resistance toward CD95L-mediated cell death. Blood 2006; 108:3371-8; PMID:16868256; http://dx.doi.org/10.1182/blood-2006-02-005660
27. Klemke CD, Fritzsching B, Franz B, Kleinmann EV, Oberle N, Poenitz N, Sykora J, Banham AH, Roncador G, Kuhn A et al. Paucity of FOXP3C cells in skin and peripheral blood distinguishes Sezary syndrome from other cutaneous T-cell lymphomas. Leukemia 2006; 20:1123-9; PMID:NOT_FOUND; http://dx.doi.org/10.1038/sj.leu.2404182
28. Matsuo T, Shimose S, Kubo T, Mikami Y, Arihiro K, Yasunaga Y, Ochi M. Extraskeletal osteosarcoma with partial spontaneous regression. Anticancer Res 2009; 29:5197-201; PMID:20044636
29. Theoleyre S, Mori K, Cherrier B, Passuti N, Gouin F, Redini F, Heymann D. Phenotypic and functional analysis of lymphocytes infiltrating osteolytic tumors: use as a possible therapeutic approach of osteosarcoma. BMC Cancer 2005; 5:123; PMID:16188028; http://dx.doi.org/10.1186/1471-2407-5-123
30. Preston CC, Maurer MJ, Oberg AL, Visscher DW, Kalli KR, Hartmann LC, Goode EL, Knutson KL. The ratios of CD8C T cells to CD4CCD25C FOXP3C and FOXP3- T cells correlate with poor clinical outcome in human serous ovarian cancer. PloS One 2013; 8:e80063; PMID:24244610; http://dx.doi.org/10.1371/journal.pone.0080063
31. Nasman A, Romanitan M, Nordfors C, Grun N, Johansson H, Hammarstedt L, Marklund L, Munck-Wikland E, Dalianis T, Ramqvist T. Tumor infiltrating CD8C and Foxp3C lymphocytes correlate to clinical outcome and human papillomavirus (HPV) status in tonsillar cancer. PloS One 2012; 7:e38711; PMID:22701698; http://dx.doi.org/10.1371/journal.pone.0038711
32. Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C et al. Intraepithelial CD8C tumor-infiltrating lymphocytes and a high CD8C/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A 2005; 102:18538-43; PMID:16344461; http://dx.doi.org/10.1073/pnas.0509182102
33. Zeestraten EC, Van Hoesel AQ, Speetjens FM, Menon AG, Putter H, van de Velde CJ, Kuppen PJ. FoxP3-and CD8-positive infiltrating immune cells together determine clinical outcome in colorectal cancer. Cancer Microenviron 2013; 6:31-9; PMID:21732187; http://dx.doi.org/10.1007/s12307-011-0071-x
34. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139
35. Gavin MA, Torgerson TR, Houston E, DeRoos P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD, Rudensky AY. Single-cell analysis of normal and FOXP3-mutant human T cells: FOXP3 expression without regulatory T cell development. Proc Natl Acad Sci U S A 2006; 103:6659-64; PMID:16617117; http://dx.doi.org/10.1073/pnas.0509484103
36. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D et al. Functional delineation and differentiation dynamics of human CD4C T cells expressing the FoxP3 transcription factor. Immunity 2009; 30:899-911; PMID:19464196; http://dx.doi.org/10.1016/j.immuni.2009.03.019
37. Morgan ME, van Bilsen JH, Bakker AM, Heemskerk B, Schilham MW, Hartgers FC, Elferink BG, van der Zanden L, de Vries RR, Huizinga TW et al. Expression of FOXP3 mRNA is not confined to CD4CCD25C T regulatory cells in humans. Hum Immunol 2005; 66:13-20; PMID:15620457; http://dx.doi.org/10.1016/j.humimm.2004.05.016
38. Roncador G, Brown PJ, Maestre L, Hue S, Martinez-Torrecuadrada JL, Ling KL, Pratap S, Toms C, Fox BC, Cerundolo V et al. Analysis of FOXP3 protein expression in human CD4CCD25C regulatory T cells at the single-cell level. Eur J Immunol 2005; 35:1681-91; PMID:15902688; http://dx.doi.org/10.1002/eji.200526189
39. Walker MR, Kasprowicz DJ, Gersuk VH, Benard A, Van Landeghen M, Buckner JH, Ziegler SF. Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4CCD25- T cells. J Clin Invest 2003; 112:1437-43; PMID:14597769; http://dx.doi.org/10.1172/JCI19441
40. Allan SE, Crome SQ, Crellin NK, Passerini L, Steiner TS, Bacchetta R, Roncarolo MG, Levings MK. Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. Int Immunol 2007; 19:345-54; PMID:17329235; http://dx.doi.org/10.1093/intimm/dxm014
41. Pillai V, Ortega SB, Wang CK, Karandikar NJ. Transient regulatory T-cells: a state attained by all activated human T-cells. Clin Immunol 2007; 123:18-29; PMID:17185041; http://dx.doi.org/10.1016/j.clim.2006.10.014
42. Wang J, Ioan-Facsinay A, van der Voort EI, Huizinga TW, Toes RE. Transient expression of FOXP3 in human activated nonregulatory CD4C T cells. Eur J Immunol 2007; 37:129-38; PMID:17154262; http://dx.doi.org/10.1002/eji.200636435
43. Bailey-Bucktrout SL, Martinez-Llordella M, Zhou X, Anthony B, Rosenthal W, Luche H, Fehling HJ, Bluestone JA. Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response. Immunity 2013; 39:949-62; PMID:24238343; http://dx.doi.org/10.1016/j.immuni.2013.10.016
44. Povoleri GA, Scotta C, Nova-Lamperti EA, John S, Lombardi G, Afzali B. Thymic versus induced regulatory T cells – who regulates the regulators? Front Immunol 2013; 4:169; PMID:23818888; http://dx.doi.org/10.3389/fimmu.2013.00169
45. Sakaguchi S, Vignali DA, Rudensky AY, Niec RE, Waldmann H. The plasticity and stability of regulatory T cells. Nat Rev Immunol 2013; 13:461-7; PMID:23681097; http://dx.doi.org/10.1038/nri3464
46. Spranger S, Spaapen RM, Zha Y, Williams J, Meng Y, Ha TT, Gajewski TF. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(C) T cells. Sci Transl Med 2013; 5:200-116; PMID:23986400; http://dx.doi.org/10.1126/scitranslmed.3006504
47. Shen JK, Cote GM, Choy E, Yang P, Harmon D, Schwab J, Nielsen GP, Chebib I, Ferrone S, Wang X et al. Programmed cell death ligand 1 expression in osteosarcoma. Cancer Immunol Res 2014; 2:690-8; PMID:24866169; http://dx.doi.org/10.1158/2326-6066.CIR-13-0224
48. Urakawa H, Nishida Y, Nakashima H, Shimoyama Y, Nakamura S, Ishiguro N. Prognostic value of indoleamine 2,3-dioxygenase expression in high grade osteosarcoma. Clin Exp Metastasis 2009; 26:1005-12; PMID:19802733; http://dx.doi.org/10.1007/s10585-009-9290-7
49. Park JY, Jang MJ, Chung YH, Kim KY, Kim SS, Lee WB, You S, Choi YS, Hur DY, Kim D. Doxorubicin enhances CD4(C) T-cell immune responses by inducing expression of CD40 ligand and 4-1BB. Int Immunopharmacol 2009; 9:1530-9; PMID:19778641; http://dx.doi.org/10.1016/j.intimp.2009.09.008
50. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C et al. Towards the introduction of the ’Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi.org/10.1002/path.4287
51. Bielack S, Whelan J, Marina N, Hook J, Jovic G, Krailo MD, Butterfass-Bahloul T, Kühne T, Eriksson M, Teot LA et al. MAP plus maintenance pegylated interferon a-2b (MAPIfn) versus MAP alone in patients with resectable high-grade osteosarcoma and good histologic response to preoperative MAP: First results of the EURAMOS-1 “good response” randomization. J Clin Oncol 2013; 31 (abstract); PMID:23669227
52. Moher D, Schulz KF, Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001; 285:1987-91; PMID:NOT_FOUND; http://dx.doi.org/10.1001/jama.285.15.1987
53. Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010; 7:e1000251; PMID:20352064; http://dx.doi.org/10.1371/journal.pmed.1000251
54. Altman DG, McShane LM, Sauerbrei W, Taube SE. Reporting recommendations for tumor marker prognostic studies (REMARK): explanation and elaboration. PLoS Med 2012; 9:e1001216; PMID:22675273; http://dx.doi.org/10.1371/journal.pmed.1001216
55. Lin IF, Chang WP, Liao YN. Shrinkage methods enhanced the accuracy of parameter estimation using Cox models with small number of events. J Clin Epidemiol 2013; 66:743-51; PMID:23566374; http://dx.doi.org/10.1016/j.jclinepi.2013.02.002
56. Vittinghoff E, McCulloch CE. Relaxing the rule of ten events per variable in logistic and Cox regression. A J Epidemiol 2007; 165:710-8; PMID:17182981; http://dx.doi.org/10.1093/aje/kwk052
57. Taylor JM, Ankerst DP, Andridge RR. Validation of biomarker-based risk prediction models. Clin Cancer Research 2008; 14:5977-83; PMID:18829476; http://dx.doi.org/10.1158/1078-0432.CCR-07-4534